PIRAMAL PHARMA LIMITED Fair Value
PPLPHARMA · Healthcare · Current price ₹179.42
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹49 | -4% ROE fading to 13% over ~3 yrs, on ₹61 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is PIRAMAL PHARMA LIMITED undervalued?
DocStoX estimates the fair value of PIRAMAL PHARMA LIMITED at ₹49 per share, versus the current market price of ₹179. That puts the stock about -72.7% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹49). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹42 (bear) to ₹49 (base) to ₹56 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on PIRAMAL PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.